These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11571818)

  • 61. Focus and impact of pharmacists' interventions.
    Strong DK; Tsang GW
    Can J Hosp Pharm; 1993 Jun; 46(3):101-8. PubMed ID: 10126864
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.
    Sikand H; Decter A; Greco T; Watson SH; Kang YJ; Mody SH; Piech CT; Duh MS; Naeem A
    Ann Pharmacother; 2008 Jan; 42(1):16-23. PubMed ID: 18029428
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacist recognition of and adherence to medication-use policies and safety practices.
    Saad AH; Sweet BV; Stumpf JL; Gruppen L; Oh M; Stevenson JG
    Am J Health Syst Pharm; 2007 Oct; 64(19):2050-4. PubMed ID: 17893416
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions.
    Khandelwal N; Duncan I; Rubinstein E; Ahmed T; Pegus C
    J Manag Care Pharm; 2012 Apr; 18(3):247-55. PubMed ID: 22468733
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Web-based survey to assess the perceptions of managed care organization representatives on use of copay subsidy coupons for prescription drugs.
    Nemlekar P; Shepherd M; Lawson K; Rush S
    J Manag Care Pharm; 2013 Oct; 19(8):602-8. PubMed ID: 24074006
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Business issues in the pharmacy. Managing pharmacy costs.
    Serb C
    Hosp Health Netw; 2005 May; 79(5):57-62, 2. PubMed ID: 15971799
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The incidence and severity of errors in pharmacist-written discharge medication orders.
    Onatade R; Sawieres S; Veck A; Smith L; Gore S; Al-Azeib S
    Int J Clin Pharm; 2017 Aug; 39(4):722-728. PubMed ID: 28573438
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization.
    Meissner B; Dickson M; Shinogle J; Reeder CE; Belazi D; Senevirante V
    J Manag Care Pharm; 2006 May; 12(4):331-40. PubMed ID: 16792439
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Controlling financial variables--changing prescribing patterns.
    Abramowitz PW
    Am J Hosp Pharm; 1984 Mar; 41(3):503-15. PubMed ID: 6367444
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Place of clinical pharmacist in the management of drugs in patients with hypertension].
    Boyé F; Sallerin B; Ah Kang F; Arnaud A; Kantambadouno JB; Amar J; Chamontin B; Bouhanick B
    Ann Cardiol Angeiol (Paris); 2015 Jun; 64(3):216-21. PubMed ID: 26051854
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan.
    Tasaka Y; Yasunaga D; Tanaka M; Tanaka A; Asakawa T; Horio I; Miyauchi Y; Araki H
    Int J Clin Pharm; 2016 Apr; 38(2):321-9. PubMed ID: 26744362
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antibacterial treatment strategies in hospitalized patients: what role for pharmacoeconomics?
    Goldman MP; Nair R
    Cleve Clin J Med; 2007 Aug; 74 Suppl 4():S38-47. PubMed ID: 17847177
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital.
    Boyko WL; Yurkowski PJ; Ivey MF; Armitstead JA; Roberts BL
    Am J Health Syst Pharm; 1997 Jul; 54(14):1591-5. PubMed ID: 9248601
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Formulary conversion from glipizide to glyburide: a cost-minimization analysis.
    Nadel HL
    Hosp Pharm; 1995 Jun; 30(6):467-9, 472-4. PubMed ID: 10142848
    [TBL] [Abstract][Full Text] [Related]  

  • 75. ASHP national survey of hospital-based pharmaceutical services--1994.
    Santell JP
    Am J Health Syst Pharm; 1995 Jun; 52(11):1179-98. PubMed ID: 7656108
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost of drugs manufactured by the university hospital--role of the Central Pharmacy.
    Marin ML; Chaves CE; Zanini AC; Faintuch J; Faintuch D; Cipriano SL
    Rev Hosp Clin Fac Med Sao Paulo; 2001; 56(2):41-6. PubMed ID: 11460203
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Projecting future drug expenditures--2004.
    Hoffman JM; Shah ND; Vermeulen LC; Hunkler RJ; Hontz KM
    Am J Health Syst Pharm; 2004 Jan; 61(2):145-58. PubMed ID: 14750400
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparative analysis of drug distribution costs for controlled versus noncontrolled oral analgesics.
    Reynolds RC; Ploetz P; Thielke TS
    Am J Hosp Pharm; 1984 Aug; 41(8):1558-63. PubMed ID: 6475974
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Costs of anesthetic drugs: experiences with a cost education trial.
    Johnstone RE; Jozefczyk KG
    Anesth Analg; 1994 Apr; 78(4):766-71. PubMed ID: 8135398
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.